
The Biden administration on Tuesday selected 10 drugs that will be part of a historic first round of price negotiation through Medicare, including the blood thinner Xarelto and Type-2 diabetes drugs Jardiance and Januvia.
Other drugs on the list treat conditions such as arthritis, heart disease, cancer and autoimmune diseases.
The announcement from the Department of Health and Human Services was a watershed moment in Democrats’ long-running push to flex government purchasing power and force down what companies charge the federal insurance program for more than 65 million seniors.
Democrats in Congress authorized the drug-negotiation program in President Biden’s signature tax and climate legislation, the Inflation Reduction Act. The complete list of drugs selected were Eliquis; Jardiance; Xarelto; Januvia; Farxiga; Entresto; Enbrel; Imbruvica; Stelara; and a series of insulins made by NovoNordisk: Fiasp, Fiasp FlexTouch, Fiasp PenFill, NovoLog, NovoLog FlexPen and NovoLog PenFill.